New Zealand markets closed

Amylyx Pharmaceuticals, Inc. (AMLX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.8400-0.0400 (-1.39%)
At close: 04:00PM EDT
2.8600 +0.02 (+0.70%)
After hours: 07:37PM EDT

Amylyx Pharmaceuticals, Inc.

43 Thorndike Street
Cambridge, MA 02141
United States
617 682 0917
https://amylyx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees384

Key executives

NameTitlePayExercisedYear born
Mr. Joshua B. CohenCo-Founder, Co-CEO & Director1MN/A1992
Mr. Justin B. KleeCo-Founder, Co-CEO & Director1MN/A1991
Mr. James M. Frates M.B.A.Chief Financial Officer695.12kN/A1967
Ms. Gina M. MazzarielloChief Legal Officer & General Counsel794.83kN/A1971
Mr. Tom HolmesChief Technical Operations OfficerN/AN/AN/A
Lindsey AllenHead of Investor Relations & CommunicationsN/AN/AN/A
Ms. Shauna HorvathHead of Global MarketingN/AN/AN/A
Ms. Linda A. ArsenaultChief Human Resources OfficerN/AN/AN/A
Mr. Chris AielloHead of Canada & GMN/AN/AN/A
Mr. Keith WhiteHead of Global Market AccessN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Amylyx Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 March 2024 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.